Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960767 | 0.83 | GRIA4 (0.32) | GPR35ALDH1A1SMN1; SMN2 | |
| SCHEMBL9960813 | 0.76 | MYC (0.44) | POLBTDP1L3MBTL1CYP1A2TSHR | |
| SCHEMBL9960649 | 0.74 | MYC (0.33) | POLBTDP1L3MBTL1ALDH1A1HTT | |
| SCHEMBL2457029 | 0.73 | ALDH1A1 (0.43) | POLBL3MBTL1ALDH1A1KMT2AHPGD | |
| SCHEMBL9960870 | 0.73 | CCNC (0.33) | HTT | |
| SCHEMBL9960704 | 0.73 | HTT (0.33) | POLBCYP1A2TSHRHTTKMT2A | |
| SCHEMBL6277246 | 0.73 | GPR35 (0.49) | GPR35POLBTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL9960677 | 0.70 | ELANE (0.34) | TDP1L3MBTL1ALDH1A1HTTKMT2A | |
| SCHEMBL9961012 | 0.70 | GRIA4 (0.33) | TSHRALDH1A1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL27926815 | 0.70 | ATM (0.36) | EDNRBEDNRAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | claimed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | claimed |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2015-10-15 | — | — | US | claimed |
| US-9102687-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2015-08-11 | — | — | US | claimed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | claimed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| EP-3004036-B1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LTD (IE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | disclosed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | disclosed |
| US-20160107977-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LIMITED (IE) | 2016-04-21 | — | — | US | disclosed |
| EP-3004036-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | Leo Laboratories Limited (IE) | 2016-04-13 | — | — | EP | disclosed |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2015-10-15 | — | — | US | disclosed |
| US-9102687-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| US-20150133543-A1 | TOPICAL GEL COMPOSITION COMPRISING AN INGENOL DERIVATIVE AND A SOLVENT MIXTURE | LEO LABORATORIES LIMITED (IE) | 2015-05-14 | — | — | US | disclosed |
| WO-2014191457-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LIMITED (IE) | 2014-12-04 | — | — | WO | disclosed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | disclosed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | GPR35 142/4885POLB 3773/4885TDP1 4714/4885 |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | GPR35 142/4885POLB 3773/4885TDP1 4714/4885 |
| US-20160107977-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | CYP51A1, ERG28, UTP20 | GPR35 828/4885POLB 2947/4885TDP1 4649/4885 |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | GPR35 142/4885POLB 3773/4885TDP1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.